- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07725523
Safety and Efficacy of OTL78 (Zopocianine)
Safety and Efficacy of OTL78 (Zopocianine), a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent, for Intraoperative Imaging of Prostate Cancer: A Phase IIb Trial
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Prostate cancer (PCa) is the second leading cause of cancer-related death behind lung cancer. Prostate cells express Prostate Specific Membrane Antigen (PSMA), which is overexpressed in PCa cells in over 90% of patients. On Target has developed a PSMA-targeted agent, the drug product OTL78, that fluoresces under NIR illumination to help with the identification of prostate cancer tissue during resection surgery that has extended beyond the capsule of the prostate into adjacent tissue and lymph nodes. Intra-operative identification of cancer tissue using real-time imaging modalities that could improve tumor identification, demarcation and lymph node involvement may provide a very useful tool to reduce the frequency of residual cancer and increase complete removal of locally involved lymph nodes.
This study is an open label trial of an imaging agent, PSMA targeted fluorescent dye (zopocianine, OTL78), in up to 32 participants with biopsy confirmed PCa who have been scheduled to undergo a laparoscopic radical prostatectomy with pelvic lymph node dissection in order to confirm the optimal dose and administration-to-surgery interval of the drug in visualizing cancerous tissue during a standard of care radical prostatectomy.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Brandon Garver
- Telefonnummer: 317-278-4766
- E-post: brwgarve@iu.edu
Studieorter
-
-
Indiana
-
Carmel, Indiana, Förenta staterna, 46032
- Indiana University Health North Hospital
-
Kontakt:
- Brandon Garver
- Telefonnummer: 317-278-4766
- E-post: brwgarve@iu.edu
-
Huvudutredare:
- Clint Bahler, MD
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University School of Medicine
-
Kontakt:
- Brandon Garver
- Telefonnummer: 317-278-4766
- E-post: brwgarve@iu.edu
-
Huvudutredare:
- Clint Bahler, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Provision of signed and dated informed consent and HIPAA form
- Male participants 18 years of age and older
Known primary prostate cancer and any one of the following:
- Grade group 3-5;
- Suspected extra-prostatic extension (EPE) or seminal vesicle invasion (SVI);
- Suspected lymph node metastasis (clinical stage cN1) by magnetic resonance imaging or by Prostate Specific Membrane Antigen positron emission tomography
- Planned to undergo a standard of care robotic prostatectomy and lymph node dissection
- Ability to understand the requirements of the study and agree to abide by the study restrictions and to return for the required assessments
- Agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including through final study visit (6 weeks) after the dose of study drug. Sperm donation is prohibited during the study and for 3 months after the dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
- Patient scheduled to have or has had a PSMA-PET Scan for surgical treatment planning within 12 months of surgery.
Exclusion Criteria:
- The surgeon plans to perform an extraperitoneal approach
- History of anaphylactic reactions to products containing indocyanine green
History of allergy to any of the components of ZOPOCIANINE:
- 2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid (DUPA)
- Polyethylene glycol-dipeptide linker
- Chlorodye
Impaired renal or hepatic function:
- Renal: creatinine clearance (eGFR) < 50 mL/min
- Hepatic: total bilirubin > 2 × upper limit of normal or ALT/AST > 3 × upper limit of normal.
- Patients with QTc interval ≥ 470 msec per electrocardiogram (ECG) at screening calculated via the Bazett formula.
- Significant acute or chronic medical, neurologic, or illness in the participant that, in the judgment of the Principal Investigator, could compromise participant safety, limit the ability to complete the study, and/or compromise the objectives of the study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 0.06mg/kg ZOPOCIANINE given 1-7 days prior to surgery
A single dose of 0.06mg/kg ZOPOCIANINE (given 1-7 days prior to surgery) used with NIR fluorescent imaging during prostatectomy and lymph node dissection for biopsy confirmed prostate cancer.
|
A single dose of 0.06mg/kg ZOPOCIANINE used with NIR fluorescent imaging during prostatectomy and lymph node dissection
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of subjects who have a Clinically Significant Event
Tidsram: Day of surgery
|
a) Histologically confirmed cancer in residual non-nodal soft tissue resected solely because of "NIR only" detection as suspicious following prostatectomy.
b) One or more resected NIR- positive lymph nodes that contain metastatic disease as confirmed by pathology.
|
Day of surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Upptäckt av primärcancer
Tidsram: Dag för kirurgi
|
För primär cancer är antalet lesioner som är antingen: fluorescenspositiva och prostatacancerpositiva (dvs sant positiva); Fluorescenspositiv men cancer negativ (dvs falskt positivt); fluorescens negativ men cancerpositiv (dvs falskt negativt); eller, fluorescens negativ och cancer negativ (dvs sann negativ).
Vi kommer att överväga sjukdomstillstånd vid fyra (4) definierade prostataregioner - höger bakre, vänster bakre, främre och vid urinblåsan
|
Dag för kirurgi
|
|
Genomförandet av förinrätten
Tidsram: Dag för kirurgi
|
Förkirurgiplanen kommer att dokumenteras och jämföras med den dokumenterade operationen som utförs om kirurg rapporterar om förändringar i omfattning från den första planen.
|
Dag för kirurgi
|
|
Detection of Metastatic Cancer
Tidsram: Day of surgery
|
For metastatic cancer spread to lymph nodes, the number of lesions that are either: fluorescence positive, and prostate cancer positive (i.e., true positive); fluorescence positive but cancer negative (i.e., false positive); fluorescence negative but cancer positive (i.e., false negative); or, fluorescence negative and cancer negative (i.e., true negative).
We will use six (6) defined lymph node regions (external iliac, internal iliac, common iliac and right and left)
|
Day of surgery
|
|
Incidence rates AEs and all SAEs
Tidsram: Screening to 6 week follow-up
|
Incidence rates of all causally related AEs and all SAEs
|
Screening to 6 week follow-up
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Clint Bahler, MD, Indiana University
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- UROL-CC-IUSCCC-0965
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .